多發性硬化症藥物市場規模、佔有率和成長分析（按類型、給藥途徑、分銷管道和地區）- 產業預測 2025-2032

2023 年多發性硬化症治療市場規模價值 284 億美元，預計將從 2024 年的 296.2 億美元成長到 2032 年的 414.8 億美元，預測期內（2025-2032 年）的複合年成長率為 4.3%。

由於疾病負擔不斷增加和對有效治療的需求不斷增加，多發性硬化症 (MS) 市場預計將經歷顯著成長。隨著多發性硬化症發病率的上升，大型製藥企業正在加強研發力度，開發創新治療方法，創造豐厚的商機。值得注意的是，Adamas Pharmaceuticals Inc. 宣布臨床實驗藥物 ADS-5102 的 3 期試驗取得了令人欣喜的結果。此外，政府旨在增加產品發布和改善治療機會的措施可能會進一步支持市場擴張。家用鼻內抗 CD3 單株抗體等新型療法的推出體現了該產業對推進 MS 治療方案的決心。總體而言，預計美國MS 藥物市場在未來的預測期內將保持持續的複合年成長率。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

多發性硬化症藥物市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• 免疫調節藥物
• 干擾素
• 免疫抑制劑
• 其他類型

多發性硬化症藥物市場規模（依給藥途徑和複合年成長率） (2025-2032)

• 市場概況
• 口服
• 腸外
• 其他

多發性硬化症藥物市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 網路藥局
• 零售藥局
• 其他分銷管道

多發性硬化症藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Biogen Inc.（United States）
• Roche Holdings AG（Switzerland）
• Novartis AG（Switzerland）
• Sanofi SA（France）
• Merck & Co., Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bayer AG（Germany）
• Pfizer Inc.（United States）
• GlaxoSmithKline plc（United Kingdom）
• AbbVie Inc.（United States）
• Johnson & Johnson Services, Inc.（United States）
• Celgene Corporation（United States）
• Bristol-Myers Squibb Company（United States）
• Mitsubishi Tanabe Pharma Corporation（Japan）
• Biogen Idec International GmbH（Switzerland）
• Genzyme Corporation（United States）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Merck KGaA（Germany）
• Mylan NV（United States）

結論和建議

Multiple Sclerosis Drugs Market size was valued at USD 28.4 billion in 2023 and is poised to grow from USD 29.62 billion in 2024 to USD 41.48 billion by 2032, growing at a CAGR of 4.3% during the forecast period (2025-2032).

The multiple sclerosis (MS) market is poised for significant growth due to an increasing disease burden and rising demand for effective therapeutics. As the prevalence of MS grows, major pharmaceutical companies are intensifying their R&D efforts to develop innovative treatments, creating lucrative opportunities. Notably, Adamas Pharmaceuticals Inc. has announced promising results from its phase 3 trial of ADS-5102, an investigational agent for MS. Additionally, product launches and government initiatives aimed at improving treatment accessibility will further support market expansion. The introduction of novel therapies, such as an intranasal anti-CD3 monoclonal antibody for at-home use, exemplifies the industry's commitment to advancing MS treatment options. Overall, the US MS drugs market is expected to maintain a sustainable CAGR in the coming forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Sclerosis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Sclerosis Drugs Market Segments Analysis

Global Multiple Sclerosis Drugs Market is segmented by Type, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Immunomodulators, Interferons, Immunosuppressants and Other types. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Other Distribution Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Multiple Sclerosis Drugs Market

The escalating prevalence of multiple sclerosis (MS) worldwide significantly propels the growth of the multiple sclerosis drugs market. According to the National Multiple Sclerosis Society, approximately 2.8 million individuals globally are affected by MS, a figure that is on the rise, particularly in more developed regions. This increasing patient population underscores the urgent need for advanced therapies aimed at managing disease progression effectively. As the demand for innovative treatment options grows, pharmaceutical companies are driven to invest in research and development to cater to the evolving needs of patients suffering from MS, further stimulating the market's expansion.

Restraints in the Multiple Sclerosis Drugs Market

The high cost associated with treatments for multiple sclerosis presents a significant obstacle to market growth. Many disease-modifying therapies, particularly those related to chemotherapy and oral medications, are priced at premium levels, rendering them inaccessible for patients lacking comprehensive insurance coverage. This financial strain is especially severe in both high-income and low-income countries where health systems may not possess the necessary resources to provide or support these expensive treatments effectively. As a result, the affordability issue creates a substantial barrier to accessing vital therapies, ultimately hindering market potential and patient care in the multiple sclerosis treatment landscape.

Market Trends of the Multiple Sclerosis Drugs Market

In the Multiple Sclerosis (MS) drugs market, a significant trend is the acceleration towards personalized medicine and biomarker-based therapies. Advances in genetics and molecular biology are facilitating the identification of specific biomarkers that predict disease progression and patient response to treatment. This shift is fostering the creation of tailored therapeutic solutions designed to optimize efficacy and minimize side effects for individuals with MS. As healthcare providers increasingly emphasize personalized treatment approaches, pharmaceutical companies are prioritizing research and development of targeted therapies, thereby reshaping the landscape of MS treatment and fostering improved outcomes and quality of life for patients.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Multiple Sclerosis Drugs Market Size by Type & CAGR (2025-2032)

• Market Overview
• Immunomodulators
• Interferons
• Immunosuppressants
• Other types

Global Multiple Sclerosis Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Multiple Sclerosis Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Global Multiple Sclerosis Drugs Market Size & CAGR (2025-2032)

• North America (Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holdings AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Idec International GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genzyme Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations